CRO directory 2026

    Clinical Research Organizations in Egypt

    Egypt is the population engine of MENA clinical research: university hospitals in Cairo, Ain Shams, Alexandria and Mansoura can enrol at a scale Gulf sites cannot, and a thicket of local CROs grew up to run bioequivalence, late-phase and investigator-initiated work under the Egyptian Drug Authority.

    IQVIA’s Cairo office delivers the country inside global Phase II–III programmes. ClinServ, a Paris-founded organisation with a Dokki desk, is the regional house sponsors still name for Egypt-plus-Levant monitoring. Advanced Research Center (ARC) in Nasr City and Genuine Research Center (GRC) in Heliopolis dominate much of the bioequivalence and healthy-volunteer work that Egyptian generic manufacturers need for EDA and GCC files. RAY CRO, Giza-based, shows up on real-world evidence and late-phase briefs. The National Research Centre in Dokki and the large university complexes — Kasr Al-Ainy, Ain Shams, Alexandria, Mansoura — plus Children’s Cancer Hospital 57357 and the National Cancer Institute, recruit the patients. EDA authorises interventional drug studies and inspects BE units. Ethics sit with hospital and faculty IRBs that are uneven in speed. This directory separates global monitors, Egyptian BE houses, regional CROs, academic sites and the Authority so a sponsor can match the vendor to the study type.

    Updated September 2026 · Egyptian Drug Authority (EDA) — clinical trial authorisation and inspected bioequivalence establishments as of September 2026 · 16 named accounts

    Request a proposal for EgyptBrowse the 16 companies

    1

    National authority that authorises drug trials and inspects BE units (EDA)

    4

    University cities that recur on industry feasibility (Cairo, Ain Shams/Abbasiya, Alexandria, Mansoura)

    2

    Study types that dominate local CRO revenue: bioequivalence for generics, and late-phase / RWE for industry

    ~1,800

    Hospitals nationwide, of which a small tertiary tier actually enrols industry patients

    Named accounts

    Top clinical research organizations (CROs) in Egypt

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Egyptian Drug Authority (EDA) — clinical trial authorisation and inspected bioequivalence establishments (as of 2026-09-04).
    #CompanyHQ
    01IQVIA EgyptCairo
    02ClinServDokki
    03Advanced Research Center (ARC)Nasr City
    04Genuine Research Center (GRC)Heliopolis
    05RAY CROGiza
    06ClinArt MENA — Cairo officeCairo
    07MCT-CRO — Egypt coverageTunis
    08Egyptian Drug Authority — clinical trialsCairo
    09National Research Centre (NRC)Dokki
    10Cairo University — Kasr Al-Ainy hospitalsCairo
    11Ain Shams University HospitalsAbbasiya
    12Alexandria University HospitalsAlexandria
    13Mansoura University HospitalsMansoura
    14Children’s Cancer Hospital 57357Cairo
    15National Cancer Institute (NCI Egypt)Cairo
    16Theodor Bilharz Research InstituteGiza

    Primary research

    These are the clinical research partners we benchmark in Egypt

    Selecting sites or a CRO in Egypt? BioNixus runs investigator and site-feasibility interviews, patient-pathway mapping and competitor-trial landscaping. Proposal within 48 hours.

    Planning research in Egypt?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in Egypt (2026)

    How the market is structured

    How sponsors open Egyptian sites and clear EDA ethics

    Pick the study type first. A bioequivalence file for an Egyptian or GCC generic usually goes to ARC, GRC or another EDA-inspected clinical pharmacology unit with a GCP ward and a GLP bioanalytical lab on one campus. A multinational Phase III goes to IQVIA or another global CRO, which then contracts Kasr Al-Ainy, Ain Shams, Alexandria University, Mansoura or 57357. A mid-sized regional protocol often lands on ClinServ, RAY or ClinArt’s Cairo team. Every interventional drug study needs EDA authorisation and a local IRB letter; insurance and a local responsible person are expected when the sponsor has no Egyptian entity. Start-up time is driven by the hospital research office as much as by the Authority — Kasr Al-Ainy and 57357 are used to industry contracts, district hospitals are not. Samples for global trials still travel to European or Gulf central labs; BE samples stay on the Cairo campus. Currency and payment delays are a CRA-retention issue, not a footnote. Feasibility that quotes “Egypt’s 100 million people” without naming a hospital research office will miss first-patient by months.

    Local

    Egyptian BE and clinical houses — ARC and GRC especially — that hold EDA-inspected wards and bioanalytical labs for generic and some patient studies.

    • Advanced Research Center (ARC)
    • Genuine Research Center (GRC)

    Multinational

    IQVIA’s Cairo country office, the global firm that still delivers most multinational Phase II–III monitoring in Egypt.

    • IQVIA Egypt

    Regional

    ClinServ, RAY, ClinArt’s Cairo node and MCT-CRO, which fold Egyptian sites into Levant, Gulf and Maghreb contracts.

    • ClinServ
    • RAY CRO
    • ClinArt MENA — Cairo office
    • MCT-CRO — Egypt coverage

    Sites, SMOs & regulators

    EDA as authoriser, NRC as national lab, and the university and charity hospitals that enrol — Kasr Al-Ainy, Ain Shams, Alexandria, Mansoura, 57357, NCI, Theodor Bilharz.

    • Egyptian Drug Authority — clinical trials
    • National Research Centre (NRC)
    • Cairo University — Kasr Al-Ainy hospitals
    • Ain Shams University Hospitals
    • Alexandria University Hospitals
    • Mansoura University Hospitals
    • Children’s Cancer Hospital 57357
    • National Cancer Institute (NCI Egypt)
    • Theodor Bilharz Research Institute

    What is moving

    What is moving clinical research in Egypt

    University-hospital enrolment scale

    Kasr Al-Ainy, Ain Shams, Alexandria and Mansoura can still put up monthly numbers that Gulf private hospitals cannot, which keeps Egypt on global feasibility lists.

    A standing bioequivalence industry

    Domestic generic houses need EDA and GCC BE packages, which keeps ARC, GRC and peer units busy independently of multinational Phase III cycles.

    EDA as a single door

    One Authority for product and trial files beats the older split-agency era, even when hospital IRBs remain the slower clock.

    Specialist charity and institute sites

    57357, NCI and Theodor Bilharz give paediatric oncology, adult oncology and hepatic protocols a professionalised home outside the general university crush.

    BioNixus fieldwork

    How BioNixus studies clinical research organizations (CROs) in Egypt

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Egypt:
    • Investigator and coordinator interviews at Kasr Al-Ainy, Ain Shams and 57357 on query load, monitoring cadence and payment delays.
    • On-campus capability checks at ARC (Nasr City) and GRC (Heliopolis) that record bed counts, bioanalytical scope and recent inspector visits.
    • EDA and IRB timeline reconstruction for interventional versus BE submissions completed in the last two years.
    • Enrolment-pool estimates for oncology and cardiometabolic protocols across Cairo, Alexandria and Mansoura, including competing-study overlap.

    Clinical Research Organizations market research in Egypt

    Questions

    Frequently Asked Questions

    Can a foreign sponsor file an Egyptian trial without a local company?

    EDA expects a locally accountable person or organisation. A licensed CRO commonly holds the correspondence, insurance liaison and GCP face to the Authority.

    Who does bioequivalence in Egypt?

    Specialist units such as ARC and GRC, not the global Phase III houses. Pick them when the product is a generic file; pick IQVIA or a regional full-service CRO when the product is an innovative multinational protocol.

    Which hospitals should be on a first feasibility list?

    Kasr Al-Ainy and Ain Shams in Cairo, Alexandria University, Mansoura for Delta catchments, 57357 for paediatric oncology, NCI for adult oncology. Add Theodor Bilharz when the question is liver or endemic disease.

    How long does start-up take?

    The EDA clock is only half the story. Hospital research-office and IRB time varies sharply by faculty. Sponsors should budget from recent comparable submissions at the named site, not from a single national average.

    How does BioNixus research CROs in Egypt?

    Principal-investigator and coordinator interviews at Kasr Al-Ainy, Ain Shams, Alexandria and 57357; BE-unit capability checks in Nasr City and Heliopolis; and EDA timeline reconstruction from recent interventional and BE submissions.

    Does placement in the table mean one Egyptian CRO outranks another?

    Placement means role. BE houses, global monitors, regional CROs, academic sites and the Authority are grouped so a sponsor can match vendor to study type, not so a league table can be read down the page.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Egypt. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Egyptian Drug Authority (EDA) — clinical trial authorisation and inspected bioequivalence establishments, consulted 2026-09-04. Company classification (Local / MNC / Regional / sites, smos & regulators) reflects ownership and role in Egypt, not size.

    • Egyptian Drug Authority clinical-trial and establishment materials
    • Company descriptions of ClinServ, ARC, GRC, RAY CRO and IQVIA Egypt; ClinArt/CTI Cairo coverage
    • Research-office materials of Kasr Al-Ainy, Ain Shams, 57357, NCI and Theodor Bilharz
    • BioNixus Egypt site-feasibility, BE-unit and sponsor fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need site and investigator intelligence in Egypt?

    Feasibility, recruitment realism and investigator preference — from the sites, not the sponsor deck.

    Planning research in Egypt?

    Primary research, market access & HEOR. Proposals within 48 hours.